Jennifer C Reid
Overview
Explore the profile of Jennifer C Reid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollands C, Boyd A, Zhao X, Reid J, Henly C, ElRafie A, et al.
Cell Rep Med
. 2024 Apr;
5(4):101485.
PMID: 38582086
Despite most acute myeloid leukemia (AML) patients entering remission following chemotherapy, outcomes remain poor due to surviving leukemic cells that contribute to relapse. The nature of these enduring cells is ...
2.
Boyd A, Lu J, Hollands C, Alsostovar L, Murali S, Reid J, et al.
Cell Rep Med
. 2023 Jul;
4(7):101108.
PMID: 37433297
We systematically investigate functional and molecular measures of stemness in patients with acute myeloid leukemia (AML) using a cohort of 121 individuals. We confirm that the presence of leukemic stem...
3.
Orlando L, Benoit Y, Reid J, Nakanishi M, Boyd A, Garcia-Rodriguez J, et al.
Cell Chem Biol
. 2023 Jun;
30(7):780-794.e8.
PMID: 37379846
Overlapping principles of embryonic and tumor biology have been described, with recent multi-omics campaigns uncovering shared molecular profiles between human pluripotent stem cells (hPSCs) and adult tumors. Here, using a...
4.
Golubeva D, Porras D, Doyle M, Reid J, Tanasijevic B, Boyd A, et al.
Stem Cells Transl Med
. 2023 May;
12(6):334-354.
PMID: 37226319
Screening of primary patient acute myeloid leukemia (AML) cells is challenging based on intrinsic characteristics of human AML disease and patient-specific conditions required to sustain AML cells in culture. This...
5.
Vandersluis S, Reid J, Orlando L, Bhatia M
Drug Discov Today
. 2022 Oct;
27(12):103407.
PMID: 36243303
The discovery and development of effective drugs for cancer patients has seen limited success in the clinic from phase I trials onward. The high attrition rate of current drug development...
6.
Porras D, Reid J, Tanasijevic B, Golubeva D, Boyd A, Bhatia M
Cells
. 2022 Jun;
11(12).
PMID: 35741044
The generation of human hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) represents a major goal in regenerative medicine and is believed would follow principles of early development....
7.
Reid J, Golubeva D, Boyd A, Hollands C, Henly C, Orlando L, et al.
Cell Rep
. 2021 Mar;
34(11):108845.
PMID: 33730576
Identifying precise targets of individual cancers remains challenging. Chronic lymphocytic leukemia (CLL) represents the most common adult hematologic malignancy, and trisomy 12 (tri12) represents a quarter of CLL patients. We...
8.
Orlando L, Tanasijevic B, Nakanishi M, Reid J, Garcia-Rodriguez J, Chauhan K, et al.
Cell Rep
. 2021 Mar;
34(10):108818.
PMID: 33691101
Histone variants (HVs) are a subfamily of epigenetic regulators implicated in embryonic development, but their role in human stem cell fate remains unclear. Here, we reveal that the phosphorylation state...
9.
Aslostovar L, Boyd A, Benoit Y, Lu J, Garcia Rodriguez J, Nakanishi M, et al.
Cell Rep Med
. 2021 Mar;
2(2):100202.
PMID: 33665638
The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Here, we access...
10.
Nakanishi M, Mitchell R, Benoit Y, Orlando L, Reid J, Shimada K, et al.
Cell
. 2019 Apr;
177(4):910-924.e22.
PMID: 30982595
The assembly of organized colonies is the earliest manifestation in the derivation or induction of pluripotency in vitro. However, the necessity and origin of this assemblance is unknown. Here, we...